Retatrutide Clinical Trials: Latest Phase 3 Results & Research
Retatrutide clinical trials have generated major interest in metabolic medicine research. Researchers know retatrutide by its development code, LY3437943. It targets three hormone receptors: GIP, GLP-1, and glucagon. This triple-agonist approach makes it different from most existing therapies.
Clinical trials continue to test retatrutide’s potential applications, safety, and effectiveness. Researchers are still gathering data across multiple trial phases. Retatrutide remains investigational. No regulator has approved it as a medication.
This article walks through what these trials have found so far, from early Phase 1 work through the current Phase 3 program.
What Are Retatrutide Clinical Trials?
Clinical trials test whether a drug works and whether it’s safe. Researchers run trials in phases, and each phase answers a different question.
Phase 1 trials test safety in a small group of people. Phase 2 trials expand testing and start looking at effectiveness. Researchers also compare different doses at this stage.
Phase 3 trials involve much larger groups. They compare the drug against a placebo or an existing treatment. Regulators rely heavily on Phase 3 data when reviewing a drug for approval. Retatrutide clinical trials have moved through all three phases, and the Phase 3 program is now largely complete.
What Is Retatrutide?
Eli Lilly developed retatrutide, also known as LY3437943. It’s a synthetic peptide that activates three receptors at once: GIP, GLP-1, and glucagon. Researchers call this a triple agonist.
GLP-1 receptor activity suppresses appetite and slows digestion. GIP receptor activity supports insulin release after meals. Glucagon receptor activity raises energy expenditure, meaning the body burns more calories at rest.
This three-pathway combination sets retatrutide apart from single- or dual-target drugs. It’s one reason retatrutide clinical trials have drawn so much scientific attention. Retatrutide remains investigational, however. It isn’t an approved treatment, and this article doesn’t provide dosing guidance.
Retatrutide Phase 1 and Phase 2 Research
Early-stage trials focused on safety and tolerability first. Researchers tracked how the body processed retatrutide and watched for side effects. These studies also measured early signals of effectiveness.
Key Phase 2 Findings
A 2023 Phase 2 trial published in the New England Journal of Medicine involved 338 participants over 48 weeks. Researchers tested several doses against a placebo.
The 12 mg dose produced average weight loss of 24.2%. The placebo group lost 2.1%. These results positioned retatrutide as the most advanced triple agonist in the obesity drug pipeline at the time. Researchers used this data to design the larger Phase 3 program that followed.
Retatrutide Phase 3 Clinical Trials
Retatrutide’s Phase 3 program splits into two related tracks. TRIUMPH covers obesity and related conditions. TRANSCEND covers type 2 diabetes specifically.
TRIUMPH Clinical Trials
The TRIUMPH program tests retatrutide across several obesity-related populations. Different TRIUMPH trials study different groups, including people with obesity alone, obesity with type 2 diabetes, and obesity with cardiovascular disease. Together, these trials have enrolled thousands of participants worldwide.
TRIUMPH-1
TRIUMPH-1 is the pivotal trial for obesity. It enrolled 2,339 patients and tracked outcomes over 80 weeks. Participants reported an average weight loss of 28.3%. An extension cohort of patients with a BMI of 35 or higher reached 30.3% weight loss at 104 weeks.
TRIUMPH-2
TRIUMPH-2 studied participants with both obesity and type 2 diabetes. The trial enrolled 1,152 patients. Researchers reported weight loss of up to 20.8% and HbA1c reductions of up to 1.6 percentage points at 80 weeks.
TRIUMPH-3
TRIUMPH-3 focused on participants with obesity and established cardiovascular disease. It enrolled 1,949 patients. Researchers reported weight loss of up to 22.6% at 80 weeks, along with improvements in triglycerides, blood pressure, and inflammatory markers. These are topline results. Full peer-reviewed data may still be pending publication.
Retatrutide and Type 2 Diabetes Trials
The TRANSCEND-T2D program evaluates retatrutide specifically in people with type 2 diabetes. Researchers want to know how well retatrutide controls blood sugar as a standalone therapy.
TRANSCEND-T2D-1 was the first trial in this program to report results. It tracked 537 participants with inadequately controlled type 2 diabetes over 40 weeks. Researchers measured changes in A1c and body weight.
The 12 mg dose lowered A1c by an average of 1.94 percentage points. It also produced average weight loss of 15.3%, compared with 2.6% for placebo. Researchers also tracked cardiovascular markers, including triglycerides and blood pressure, and reported improvements alongside the glycemic results.
What Have Retatrutide Clinical Trials Found?
Across Phase 2 and Phase 3 trials, several themes have emerged consistently. Clinical trials have reported substantial weight loss across multiple patient populations, often exceeding results seen with earlier incretin-based drugs.
Researchers observed meaningful improvements in blood sugar control among people with type 2 diabetes. Early findings also suggest benefits for cardiovascular risk markers and liver fat, though these areas need further study.
The available evidence indicates a safety profile broadly similar to other drugs in this class, dominated by gastrointestinal side effects. Researchers continue to evaluate long-term safety and durability of results.
Retatrutide vs Other Incretin-Based Treatments
Retatrutide isn’t the only hormone-based therapy under study or in use. Semaglutide and tirzepatide target overlapping but different receptor combinations.
| Feature | Retatrutide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | GLP-1 | GIP, GLP-1 |
| Status | Investigational | Approved indications vary by product | Approved indications vary by product |
| Research focus | Metabolic research | Metabolic and other approved indications | Metabolic and other approved indications |
Researchers shouldn’t compare results across these trials too directly. Each program uses different study designs, patient populations, and follow-up periods. A fair comparison requires a dedicated head-to-head trial, and limited direct comparison data exists so far.
Retatrutide Clinical Trial Safety
Researchers monitor safety closely throughout every phase of testing. They track adverse events, lab values, and patient-reported symptoms during each trial.
Reported data show that gastrointestinal side effects, like nausea and vomiting, occur most often. These effects tend to be mild to moderate. They also cluster during dose escalation, when patients first start or increase their dose.
Clinical researchers continue to evaluate retatrutide’s safety profile as more trials report data. This article doesn’t offer personal medical advice. It also doesn’t provide instructions for using retatrutide outside a supervised clinical trial.
Is Retatrutide FDA Approved?
No. The FDA hasn’t approved retatrutide for any use. It remains an investigational drug still under study.
Clinical-trial research and FDA approval aren’t the same thing. Positive Phase 3 results support a future approval application, but they don’t guarantee one. Products marketed online as “retatrutide” outside a regulated trial or licensed pharmacy aren’t FDA-approved medicines, regardless of their marketing claims.
What Happens After Phase 3?
Successful Phase 3 trials don’t automatically lead to approval. After completing Phase 3, a company typically submits its data to regulators for review.
Regulators evaluate the full data package, including safety, effectiveness, and manufacturing information. They often ask follow-up questions or request additional data during this process.
If regulators approve the drug, safety monitoring continues afterward. Eli Lilly has indicated plans to submit retatrutide data to the FDA in early 2027, based on its completed core trials.
Frequently Asked Questions About Retatrutide Clinical Trials
What are retatrutide clinical trials?
Retatrutide clinical trials are research studies testing the investigational drug’s safety and effectiveness. They span Phase 1 through Phase 3, covering obesity, type 2 diabetes, and related metabolic conditions.
Is retatrutide in Phase 3 trials?
Yes. Retatrutide has completed several Phase 3 trials, including TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRANSCEND-T2D-1. Additional trials within these programs may still be ongoing or awaiting full publication.
What are TRIUMPH retatrutide trials?
TRIUMPH is retatrutide’s Phase 3 program for obesity and related conditions. It includes multiple trials studying different patient populations, including people with cardiovascular disease and type 2 diabetes alongside obesity.
What is the TRANSCEND-T2D retatrutide trial?
TRANSCEND-T2D is retatrutide’s Phase 3 program focused on type 2 diabetes. TRANSCEND-T2D-1, the first trial to report results, showed meaningful A1c and weight reductions over 40 weeks.
Has retatrutide been approved by the FDA?
No. Retatrutide remains investigational. Eli Lilly plans to submit its Phase 3 data to the FDA for review in early 2027, based on public statements.
Where can I find reliable retatrutide clinical-trial information?
Look to ClinicalTrials.gov, peer-reviewed journals, and official statements from Eli Lilly. These sources distinguish topline announcements from fully published, peer-reviewed results.
Conclusion: What Retatrutide Clinical Trials Tell Us
Retatrutide clinical trials have tracked a fast-moving research program. LY3437943 targets three metabolic receptors at once, and researchers have studied it across Phase 1, 2, and 3 trials. The TRIUMPH and TRANSCEND-T2D programs have reported substantial weight loss and glycemic improvements so far. Researchers still need more data on long-term safety and durability. Regulatory review remains an essential next step before retatrutide could become an approved treatment.
